Lung Cancer
Conditions
Keywords
stage IIIA non-small cell lung cancer, stage IIIB non-small cell lung cancer
Brief summary
RATIONALE: Drugs used in chemotherapy, such as cisplatin and vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. It is not yet known whether giving combination chemotherapy followed by radiation therapy is more effective than giving combination chemotherapy together with radiation therapy followed by more chemotherapy in treating non-small cell lung cancer. PURPOSE: This randomized phase III trial is studying combination chemotherapy followed by radiation therapy to see how well it works compared to combination chemotherapy combined with radiation therapy followed by more chemotherapy in treating patients with stage III non-small cell lung cancer that cannot be removed by surgery.
Detailed description
OBJECTIVES: Primary * Compare the overall survival of patients with stage III non-small cell cancer treated with chemotherapy comprising cisplatin and vinorelbine ditartrate (CV) followed by radical radiotherapy versus concurrent CV chemoradiotherapy followed by CV chemotherapy. Secondary * Compare the progression-free survival of patients treated with these regimens. * Compare the local progression-free survival (local control). * Compare the hematological, pulmonary, esophageal, and neurological toxicities. * Compare the response. * Compare the quality of life. * Compare the cost-effectiveness. OUTLINE: This is a randomized, multicenter study. Patients are stratified according to clinically important factors. Patients are randomized to 1 of 2 treatment arms. * Arm I (sequential treatment): Patients receive cisplatin IV over 2 hours on day 1 and vinorelbine ditartrate IV over 5-10 minutes on days 1 and 8. Treatment repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Beginning in week 15, patients undergo radiotherapy 5 days a week for 4 weeks. * Arm II (concurrent treatment): Patients undergo radiotherapy as in arm I beginning in week 1. Patients receive cisplatin IV over 2 hours on days 1-4 and vinorelbine ditartrate IV over 5-10 minutes on days 1 and 8. Chemotherapy repeats every 3 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline, monthly for 6 months, and then at each follow-up visit. After completion of study treatment, patients are followed periodically. Peer Reviewed and Funded or Endorsed by Cancer Research UK PROJECTED ACCRUAL: A total of 508 patients will be accrued for this study.
Interventions
Four cycles of cisplatinum/vinorelbine given in a 21 day cycle followed by radical radiotherapy, 55 Gy in 20 once daily fractions in four weeks (2.75 Gy/day).
DRUGExperimental arm (CON):
concurrent chemo-radiotherapy \[55 Gy in 20 daily fractions in 4 weeks (2.75 Gy/day) with cisplatinum given concurrently with fractions 1-4 and 16-19, and vinorelbine prior to fractions 1, 6, 15 and 20\] followed by two cycles of cisplatinum/vinorelbine.
Sponsors
University College, London
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed stage III non-small cell lung cancer (NSCLC) * Patients with stage IIIB disease must not have a pleural effusion that is cytologically proven to be malignant * Inoperable disease * Disease must be able to be encompassed within a radical radiotherapy treatment volume PATIENT CHARACTERISTICS: * ECOG performance status 0 or 1 * Life expectancy \> 3 months * Patient considered able to tolerate platinum-based chemotherapy and radical radiotherapy * Glomerular filtration rate ≥ 60 mL/min * WBC \> 3,000/mm³ * Absolute neutrophil count \> 1,500/mm³ * Hemoglobin \> 10.0 g/dL * Patients with hemoglobin between 10 and 12 g/dL at randomization require a blood transfusion to ensure hemoglobin \> 12 g/dL before starting radiotherapy * Platelet count \> 100,000/mm³ * FEV\_1 ≥ 1.0 L or DLCO (transfer factor) ≥ 50% of predicted * Alkaline phosphatase ≤ 1.5 times upper limit of normal (ULN) * Gamma-glutamyl-transferase \< 1.5 times ULN * Transaminases ≤ 1.5 times ULN * Bilirubin ≤ 1.5 times ULN * No medically unstable conditions (e.g., unstable diabetes, uncontrolled arterial hypertension, infection, hypercalcemia, or ischemic heart disease) * Not pregnant or nursing * Fertile patients must agree to use effective contraception * Negative pregnancy test * No other previous or current malignant disease likely to interfere with protocol treatment or comparisons PRIOR CONCURRENT THERAPY: * No prior chemotherapy, radiotherapy, or investigational agents
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Treatment related mortality (any cause) | from randomization till death |
Secondary
| Measure | Time frame |
|---|---|
| Quality of life | at baseline, every 3 weeks for the first 6 months, then 3 monthly until 2 years, 6 monthly until 3 years, and annually thereafter |
| Cost effectiveness | at baseline, every 3 weeks for the first 6 months, then 3 monthly until 2 years, 6 monthly until 3 years, and annually thereafter |
| Hematological, pulmonary, esophageal, and neurological toxicities | From randomisation to the first 6 months |
| Local progression-free survival (local control) | From the date of randomisation to the date of first clinical evidence of progressive disease at the primary site, or death |
| Response | proportion of patients in each treatment group whose best response in the first 6 months from randomisation is complete or partial will be reported. |
| Overall survival and progression-free survival. | Overall Survival is the time between date of randomisation and date of death of any cause. Progression-free survival will be calculated from the date of randomisation to the date of first clinical evidence of progressive disease, or death. |
Countries
United Kingdom
Outcome results
None listed